Search | Clinical Trials Finder

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo, 0.15% Azelastine Hydrochloride; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 536 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Asthma, Rhinitis, Eczema, Respiratory Sounds, Hypersensitivity
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Seasonal Allergic Rhinitis
Interventions: bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose, placebo comparator nasal product; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Irvine, California

Conditions: Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions: PQ Grass, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Epinastine Nasal Spray; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 571 participants
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Influenza Infection
Interventions: VRC-FLUNPF099-00-VP (H1ssF_3928); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Allergic Rhinoconjunctivitis
Interventions: Not listed
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Rhinitis, Allergic, Seasonal
Interventions: GW685698X Aqueous Nasal Spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Woodstock, Georgia

Conditions: Seasonal Allergic Rhinitis
Interventions: Vitamin D3, Placebo, Fluticasone Propionate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Nasal CO2, Inactive Placebo Gas; Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Seasonal Allergic Rhinitis
Interventions: placebo, Mometasone nasal spray; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 25
States / cities: Stockbridge, Georgia • Louisville, Kentucky • Bethesda, Maryland + 17 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Orotic acid and Glutathione-(Nutritional Supplements); Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Seasonal Allergic Rhinitis
Interventions: fexofenadine HCl; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day, Placebo Nasal Spray; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Irvine, California

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 58
States / cities: Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more

Conditions: Healthy
Interventions: Probiotic mixture, Placebo; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Allergic Conjunctivitis to Tree Pollen or Grass Pollen
Interventions: Fluticasone furoate nasal spray, Placebo nasal spray; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: mometasone furoate nasal spray, placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Rhinitis, Allergic, Perennial and Seasonal
Interventions: FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 31
States / cities: Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more

Conditions: Seasonal Allergic Rhinitis
Interventions: substance P, substance P injections; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Oral Bacteria and Allergic Disease in Children

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

Vitamin D Plus Fluticasone Propionate

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

Clinical Equivalence Study of Mometasone Nasal Spray

Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis

Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Reduction of IgE Antibody in Human Allergic Subjects

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™